Big data against cancer - start-up Flatiron Health has been acquired by Roche

Fri, 2018 / 03 / 16

About the author

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.

Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director

Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

E-Mail More Contact Info

Nowadays, treatment for many forms of cancer can be individualized and adapted to the patients’ exact needs. In this context, the analysis of various existing real patients’ data holds enormous potential for new findings to improve individualized treatment. This fact has also been realized by the Swiss pharmaceutical group Roche, that acquired the necessary expertise by purchasing Flatiron Health.

Flatiron Health is an US-American start-up company founded in 2012, that uses real clinical data to learn from separate cancer cases for the future. Electronic cancer-patient records are created, that can be used by oncologists, academics, hospitals, researchers, and regulators to develop better treatment methods.

In mid-February, Roche announced the acquisition of all shares of Flatiron Health within the first half of this year. The price amounts to 1.9 billion US dollars; while the US-American start-up should remain as a separate unit. Roche highlighted the purchase as an important step for their personalized health care strategy, because patient data from the real world will become a key for the development of new cancer treatments.

Further enormous potentials of the digitalization of the health care sector will be discussed by experts from the digital and health care industry at d!talk healthcare at the CEBIT on June, 13^th 2018. SKC presents to you “Digital Health in one day” at this event. Please contact us for further information.

BY Prof. Matthias P. Schönermark, M.D., Ph.D., Founder and Managing Director of SKC Beratungsgesellschaft mbH and Karolin Priese, Dipl.-Kauffrau at SKC Beratungsgesellschaft mbH

Sources:
Roche Media Release
Handelsblatt: Übernahme von Flatiron Health